

# Eng Hui Chew

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3648295/publications.pdf>

Version: 2024-02-01

34  
papers

2,049  
citations

331670

21  
h-index

395702

33  
g-index

37  
all docs

37  
docs citations

37  
times ranked

3401  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12288-12293.	7.1	444
2	Inhibition of the Human Thioredoxin System. Journal of Biological Chemistry, 2008, 283, 11913-11923.	3.4	406
3	Cinnamaldehydes inhibit thioredoxin reductase and induce Nrf2: potential candidates for cancer therapy and chemoprevention. Free Radical Biology and Medicine, 2010, 48, 98-111.	2.9	131
4	Antioxidant and Nrf2 inducing activities of luteolin, a flavonoid constituent in Ixeris sonchifolia Hance, provide neuroprotective effects against ischemia-induced cellular injury. Food and Chemical Toxicology, 2013, 59, 272-280.	3.6	89
5	Functionalized aurones as inducers of NAD(P)H:quinone oxidoreductase 1 that activate AhR/XRE and Nrf2/ARE signaling pathways: Synthesis, evaluation and SAR. European Journal of Medicinal Chemistry, 2010, 45, 2957-2971.	5.5	88
6	Identification of Michael Acceptor-Centric Pharmacophores with Substituents That Yield Strong Thioredoxin Reductase Inhibitory Character Correlated to Antiproliferative Activity. Antioxidants and Redox Signaling, 2013, 19, 1149-1165.	5.4	83
7	Elucidation of Thioredoxin as a Molecular Target for Antitumor Quinols. Cancer Research, 2005, 65, 3911-3919.	0.9	79
8	Substrate-mediated Regulation of Cullin Neddylation. Journal of Biological Chemistry, 2007, 282, 17032-17040.	3.4	78
9	Pachymic acid impairs breast cancer cell invasion by suppressing nuclear factor- $\kappa$ B-dependent matrix metalloproteinase-9 expression. Breast Cancer Research and Treatment, 2011, 126, 609-620.	2.5	71
10	Characterization of cullin-based E3 ubiquitin ligases in intact mammalian cells – Evidence for cullin dimerization. Cellular Signalling, 2007, 19, 1071-1080.	3.6	61
11	Thioredoxin reductase inhibition by antitumor quinols: a quinol pharmacophore effect correlating to antiproliferative activity. FASEB Journal, 2008, 22, 2072-2083.	0.5	51
12	Design, Synthesis, and Biological Evaluation of Coupled Bioactive Scaffolds as Potential Anticancer Agents for Dual Targeting of Dihydrofolate Reductase and Thioredoxin Reductase. Journal of Medicinal Chemistry, 2017, 60, 1734-1745.	6.4	50
13	Shogaols at proapoptotic concentrations induce G2/M arrest and aberrant mitotic cell death associated with tubulin aggregation. Apoptosis: an International Journal on Programmed Cell Death, 2011, 16, 856-867.	4.9	49
14	Measurement Properties of Existing Patient-Reported Outcome Measures on Medication Adherence: Systematic Review. Journal of Medical Internet Research, 2020, 22, e19179.	4.3	43
15	A novel shogaol analog suppresses cancer cell invasion and inflammation, and displays cytoprotective effects through modulation of NF- $\kappa$ B and Nrf2-Keap1 signaling pathways. Toxicology and Applied Pharmacology, 2013, 272, 852-862.	2.8	38
16	Thioredoxin-dependent regulation of AIF-mediated DNA damage. Free Radical Biology and Medicine, 2015, 87, 125-136.	2.9	35
17	Sulforaphane and its methylcarbonyl analogs inhibit the LPS-stimulated inflammatory response in human monocytes through modulating cytokine production, suppressing chemotactic migration and phagocytosis in a NF- $\kappa$ B- and MAPK-dependent manner. International Immunopharmacology, 2015, 24, 440-450.	3.8	34
18	Induction of Tumor Cell Death through Targeting Tubulin and Evoking Dysregulation of Cell Cycle Regulatory Proteins by Multifunctional Cinnamaldehydes. PLoS ONE, 2012, 7, e50125.	2.5	33

#	ARTICLE	IF	CITATIONS
19	Applying the designed multiple ligands approach to inhibit dihydrofolate reductase and thioredoxin reductase for anti-proliferative activity. <i>European Journal of Medicinal Chemistry</i> , 2016, 115, 63-74.	5.5	32
20	Novel dual-targeting anti-proliferative dihydrotriazine-chalcone derivatives display suppression of cancer cell invasion and inflammation by inhibiting the NF- $\kappa$ B signaling pathway. <i>Food and Chemical Toxicology</i> , 2018, 116, 238-248.	3.6	23
21	Indolin-2-one compounds targeting thioredoxin reductase as potential anticancer drug leads. <i>Oncotarget</i> , 2016, 7, 40233-40251.	1.8	23
22	Association of obesity with patient-reported outcomes in patients with axial spondyloarthritis: a cross-sectional study in an urban Asian population. <i>Clinical Rheumatology</i> , 2017, 36, 2365-2370.	2.2	20
23	Antitumor quinols: Role of glutathione in modulating quinol-induced apoptosis and identification of putative cellular protein targets. <i>Biochemical and Biophysical Research Communications</i> , 2006, 346, 242-251.	2.1	18
24	Measurement properties of patient reported outcome measures for spondyloarthritis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 274-282.	3.4	14
25	Studies on the Chemical Constituents and Biological Activities of <i>Ixeris</i> . <i>Chemistry and Biodiversity</i> , 2013, 10, 1373-1391.	2.1	11
26	A systematic review of the association of obesity with the outcomes of inflammatory rheumatic diseases. <i>Singapore Medical Journal</i> , 2019, 60, 270-280.	0.6	11
27	Validity and reliability of the ten-item Connor-Davidson Resilience Scale (CD-RISC10) instrument in patients with axial spondyloarthritis (axSpA) in Singapore. <i>Rheumatology International</i> , 2019, 39, 105-110.	3.0	10
28	3-(2-oxoethylidene)indolin-2-one Derivatives Activate Nrf2 and Inhibit NF- $\kappa$ B: Potential Candidates for Chemoprevention. <i>ChemMedChem</i> , 2014, 9, 1763-1774.	3.2	5
29	Validity and reliability of the Assessment of Spondyloarthritis International Society Health Index in English-speaking patients with axial spondyloarthritis in Singapore. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1644-1651.	1.9	5
30	A systematic review of the factors associated with the initiation of biologicals in patients with rheumatological conditions. <i>European Journal of Hospital Pharmacy</i> , 2019, 26, 163-169.	1.1	4
31	Development of an Item Bank to Measure Medication Adherence: Systematic Review. <i>Journal of Medical Internet Research</i> , 2020, 22, e19089.	4.3	3
32	Development of a Probiotics Practice E-Reference Database for Health Care Professionals. <i>Clinical Therapeutics</i> , 2021, 43, e364-e376.e3.	2.5	1
33	Elucidating the role of a positive family history in differentiating between axial and peripheral spondyloarthritis: an ancillary analysis of the ASAS-PerSpA study. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	0
34	Elucidating the role of a positive family history in differentiating between axial and peripheral spondyloarthritis: an ancillary analysis of the ASAS-PerSpA study.. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0